Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15222MR)

This product GTTS-WQ15222MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFSF13&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001198622.2; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8741; 10673
UniProt ID Q2QBA2; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15222MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15577MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ4002MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ8749MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ15928MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ5573MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ7073MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ2334MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ7296MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW